MorphoSys completes safety run-in of MOR208 in L-MIND combination study in patients with DLBCL
Six patients have been administered MOR208 at the recommended dose (12mg/kg) in combination with lenalidomide during the safety run-in part of the L-MIND study. No unexpected safety signals
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.